| scholarly article | Q13442814 |
| P50 | author | Abel J Bronkhorst | Q89982354 |
| Helen M Moore | Q89982357 | ||
| Muhammed Murtaza | Q43106000 | ||
| Mark D Pertile | Q56851646 | ||
| P2093 | author name string | Kelly B Engel | |
| Sarah R Greytak | |||
| Sonya Parpart-Li | |||
| P2860 | cites work | Donor-specific Cell-Free DNA as a Biomarker in Solid Organ Transplantation. A Systematic Review | Q57282168 |
| Biospecimen reporting for improved study quality (BRISQ) | Q57419587 | ||
| Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors | Q58704645 | ||
| Influence of storage conditions and extraction methods on the quantity and quality of circulating cell-free DNA (ccfDNA): the SPIDIA-DNAplas External Quality Assessment experience | Q60315416 | ||
| The emerging role of cell-free DNA as a molecular marker for cancer management | Q64078507 | ||
| Considerations and quality controls when analyzing cell-free tumor DNA | Q64263552 | ||
| Prenatal diagnosis of myotonic dystrophy using fetal DNA obtained from maternal plasma | Q73406198 | ||
| Fetal cell-free plasma DNA concentrations in maternal blood are stable 24 hours after collection: analysis of first- and third-trimester samples | Q78734317 | ||
| Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies | Q88461855 | ||
| Low-pass Whole-genome Sequencing of Circulating Cell-free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort | Q90928590 | ||
| Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time? | Q91224694 | ||
| Performance comparison of blood collection tubes as liquid biopsy storage system for minimizing cfDNA contamination from genomic DNA | Q91325805 | ||
| Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study | Q91809276 | ||
| Guidelines for the Preanalytical Conditions for Analyzing Circulating Cell-Free DNA | Q91814099 | ||
| Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer | Q92040348 | ||
| Preanalytics and Precision Pathology: Pathology Practices to Ensure Molecular Integrity of Cancer Patient Biospecimens for Precision Medicine | Q92071769 | ||
| Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer | Q92482568 | ||
| Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence | Q93137216 | ||
| Implementing prenatal diagnosis based on cell-free fetal DNA: accurate identification of factors affecting fetal DNA yield | Q28744238 | ||
| Detection of circulating tumor DNA in early- and late-stage human malignancies | Q29615778 | ||
| Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer | Q34100603 | ||
| The Occurrence of Single-Stranded DNA in the Serum of Patients with Systemic Lupus Erythematosus and Other Diseases | Q34215374 | ||
| Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus | Q34224780 | ||
| Neoplastic characteristics of the DNA found in the plasma of cancer patients | Q34543792 | ||
| Optimizing blood collection, transport and storage conditions for cell free DNA increases access to prenatal testing | Q34706270 | ||
| Optimizing the yield and utility of circulating cell-free DNA from plasma and serum. | Q34961717 | ||
| Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA. | Q36145554 | ||
| The In Vitro Stability of Circulating Tumour DNA. | Q36222235 | ||
| Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. | Q37646889 | ||
| Circulating cell free DNA: Preanalytical considerations | Q38111116 | ||
| Cell-free DNA for diagnosing myocardial infarction: not ready for prime time | Q38425367 | ||
| Cell-free DNA: Preanalytical variables | Q38581212 | ||
| Noninvasive nucleic acid-based approaches to monitor placental health and predict pregnancy-related complications. | Q38597295 | ||
| Results of the first external quality assessment scheme (EQA) for isolation and analysis of circulating tumour DNA (ctDNA). | Q38637257 | ||
| The role of total cell-free DNA in predicting outcomes among trauma patients in the intensive care unit: a systematic review | Q39101409 | ||
| Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers | Q40056869 | ||
| Noninvasive Prenatal Diagnosis of Single-Gene Disorders by Use of Droplet Digital PCR. | Q45873918 | ||
| Cell-free DNA as a biomarker in stroke: Current status, problems and perspectives | Q47206216 | ||
| Blood Collection and Cell-Free DNA Isolation Methods Influence the Sensitivity of Liquid Biopsy Analysis for Colorectal Cancer Detection | Q47548547 | ||
| Circulating tumoral DNA: Preanalytical validation and quality control in a diagnostic laboratory | Q47596249 | ||
| Detection and localization of surgically resectable cancers with a multi-analyte blood test. | Q48216212 | ||
| Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer. | Q48502619 | ||
| The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA. | Q50276908 | ||
| Influence of temperature during transportation on cell-free DNA analysis. | Q53191016 | ||
| A new methodology to preserve the original proportion and integrity of cell-free fetal DNA in maternal plasma during sample processing and storage. | Q53334658 | ||
| Free DNA in the serum of cancer patients and the effect of therapy. | Q55492005 | ||
| Presence of fetal DNA in maternal plasma and serum | Q57075132 | ||
| P577 | publication date | 2020-03-02 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Harmonizing cell-free DNA Collection and Processing Practices through Evidence-based Guidance |
Search more.